research Selectively Targeting JAK1 or JAK3 Pathway Is Sufficient to Reverse Alopecia Areata
Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.
Search
for
Sort by
Research
30 / 39 resultsresearch JAK Inhibition in the Treatment of Alopecia Areata: A Promising New Dawn?
JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
research Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata
Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research Targeting the Janus Kinase Family in Autoimmune Skin Diseases
Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
research The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
research Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study
Baricitinib is effective and safe for treating severe alopecia areata.
research Systemic Treatments for Alopecia Areata: A Systematic Review
No systemic treatment for alopecia areata has strong evidence of effectiveness.
research An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata
Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
research New Drugs Under Investigation for the Treatment of Alopecias
New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
research Application of Baricitinib in Dermatology
Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.
research Under Development JAK Inhibitors for Dermatologic Diseases
New JAK inhibitor drugs show promise for treating skin diseases but need more research on safety and effectiveness.
research Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan
Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.
research Inhibition of T-Cell Activity in Alopecia Areata: Recent Developments and New Directions
New treatments targeting T-cell pathways are needed for better alopecia areata management.
research The Evaluation of JAK Inhibitors on Effect and Safety in Alopecia Areata: A Systematic Review and Meta-Analysis of 2018 Patients
JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
research Janus Kinase Inhibitors in the Treatment of Alopecia Areata
JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
research Clinical Trials and Hair Loss
Many treatments for hair loss show potential, but more testing is needed to confirm their effectiveness. Only minoxidil for women and minoxidil and finasteride for men are FDA approved.
research Comparative Efficacy and Safety of JAK Inhibitors in the Treatment of Moderate-to-Severe Alopecia Areata: A Systematic Review and Network Meta-Analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the Allegro Phase 2b/3 Study
Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
research Treatment Patterns and Unmet Needs in the Management of Alopecia Areata: Results of a Physician’s Survey in the Middle East
Doctors in the Middle East need better treatments and more knowledge about new therapies for hair loss condition Alopecia Areata.
research Small Molecule Inhibitors and Inflammatory Skin Diseases
New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.
research The JAK/STAT Signaling Pathway: From Bench to Clinic
The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
research A Subset of TREM2+ Dermal Macrophages Secretes Oncostatin M to Maintain Hair Follicle Stem Cell Quiescence and Inhibit Hair Growth
Certain immune cells in the skin release a protein that stops hair growth by keeping hair stem cells inactive.
research JAK Inhibitors for Treatment of Alopecia Areata
JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
research Treatment of Pediatric Alopecia Areata: A Systematic Review
Topical corticosteroids are the best initial treatment for children's alopecia areata.
research Cyclosporine for Moderate-to-Severe Alopecia Areata: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of Efficacy and Safety
Cyclosporine showed some improvement in alopecia areata but results were not statistically significant.
research Selective Inhibition of JAK3 Signaling Is Sufficient to Reverse Alopecia Areata
Blocking JAK3 signaling can reverse hair loss from alopecia areata.
research Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature
JAK inhibitors show promise for treating hair loss in alopecia areata but need more clinical trials to confirm safety and effectiveness.
research Hidradenitis Suppurativa and Comorbid Disorder Biomarkers, Druggable Genes, New Drugs and Drug Repurposing—A Molecular Meta-Analysis
The study found key factors in the cause of hidradenitis suppurativa, its link to other diseases, and identified existing drugs that could potentially treat it.